Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mannitol inhalation diagnostic/theranostic - Pharmaxis

Drug Profile

Mannitol inhalation diagnostic/theranostic - Pharmaxis

Alternative Names: Aridol; Osmohale

Latest Information Update: 19 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmaxis
  • Developer Allertec Hellas; Nigaard Pharma; Pharmaxis; Praxis Pharmaceuticals; Trimedal
  • Class Anti-inflammatories; Antiallergics; Antibronchitics; Antifibrotics; Mucolytics; Small molecules; Sugar alcohols
  • Mechanism of Action Osmotic diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Dec 2018 Launched for Asthma (Diagnosis) in USA (Inhalation)
  • 15 Aug 2018 Pharmaxis plans to relaunch Aridol® into the US market later in 2018 via Methapharm, its exclusive distribution partner
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top